Investorideas.com

Rated as a top Investment site for 2025!

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS


Apollo Silver Corp. (TSX.V:APGO, OTCQB:APGOF, Frankfurt:6ZF0)


 


investorideas.com - A Leading Global Investor Website for Biotech Industry Stocks

Investing in biotechnology, pharmaceutical, medical technology, and telemedicine stocks has reached a fever pitch in 2025, fueled by groundbreaking innovations reshaping healthcare and technology. Global biotech venture funding hit $30.2 billion in 2024, a clear sign of investor enthusiasm, and 2025 is already seeing blockbuster FDA approvals - think 10 new drugs greenlit by February alone, outpacing last year's cadence. From AI-powered drug discovery to telemedicine's explosive growth (projected U.S. market size: $87 billion by year-end), the opportunities are staggering. Let Investor Ideas steer you toward your next big win with our free stock directories and news alerts. Check out standout players like Vertex Pharmaceuticals ($VRTX), a biotech titan dominating cystic fibrosis and expanding into gene-editing therapies like Casgevy, with Q1 2025 sales topping $2.8 billion. Pfizer ($PFE) remains a pharma powerhouse, leveraging its mRNA expertise beyond COVID-19 into flu vaccines, with analysts eyeing a 12% revenue bump this year. In medical tech, Intuitive Surgical ($ISRG) is soaring, its da Vinci robotic systems logging over 2 million procedures in 2024, with 2025 forecasts showing 15% growth. And don't sleep on telemedicine leader Teladoc Health ($TDOC), riding a 20% user surge as virtual care becomes the norm. Don't miss your shot to invest in the future of healthcare and technology - 2025 is the year to act!

Biotech Stocks Directory    Get News Alerts on Biotech Stocks


Featured Biotech Stocks

Investorideas Featured Company: Aethlon Medical, Inc. (NASDAQ: AEMD)

Aethlon Medical, Inc. (NASDAQ: AEMD) is a medical therapeutic company focused on developing the Hemopurifier, a clinical stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses and harmful exosomes from blood utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where exosomes may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Get news alerts on this company!

Biotech News

Medical Tech Stock Aethlon Medical, Inc. (NASDAQ: AEMD) Reports Positive Data Safety Monitoring Board Review and Recommendation to Advance to Next Clinical Trial Cohort
SAN DIEGO - July 15, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage biotechnology company developing the investigational Aethlon Hemopurifier, an extracorporeal device for Oncology and other indications, today announced that the independent Data Safety Monitoring Board (DSMB) overseeing its ongoing clinical trial AEMD-2022-06 has completed its scheduled safety review and recommended advancing to the next patient cohort without modification.

Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Reports Financial Results for the Fiscal Fourth Quarter Ended March 31, 2025, and Provides Corporate Update
SAN DIEGO - June 27, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, reported financial results for its fiscal fourth quarter ended March 31, 2025, and provided an update on recent developments.

Medical Tech Stock Aethlon Medical (Nasdaq: AEMD) Treats Second Patient in Australian Hemopurifier Cancer Trial
SAN DIEGO - June 18, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced a significant milestone: the treatment of the second patient with the Hemopurifier in its Australian safety, feasibility and dose-finding clinical trial of the Hemopurifier.

Medical Tech News - Aethlon Medical (NASDAQ: AEMD) to Present New Pre-Clinical Data on Long COVID and Post-Acute Infection Syndromes
SAN DIEGO - June 9, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced that an abstract has been accepted for poster presentation at the Keystone Symposium on Long COVID and Other Post-Acute Infection Syndromes being held at Eldorado Hotel and Spa, Santa Fe, NM, United States, August 10-13,2025

Breaking Medical Technology News: Aethlon Medical (NASDAQ: AEMD) Announces Publication of Preclinical Data Showing Ability of the Hemopurifier to Remove Platelet-Derived Extracellular Vesicles from Plasma
SAN DIEGO - May 15, 2025 (Investorideas.com Newswire) Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today announced the publication of a pre-clinical ex vivo study in pre-print vehicle bioRxiv, entitled, "Ex Vivo Removal of CD41 positive platelet microparticles from Plasma by a Medical Device containing a Galanthus nivalis agglutinin (GNA) affinity resin."

Biotech Stock Mural Oncology (Nasdaq: MURA) Makes NASDAQ Top Gainer List on News
April 15, 2025 (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Mural Oncology (Nasdaq: MURA), a clinical-stage immuno-oncology company.

Biotech Stock Sunshine Biopharma Inc. (NASDAQ:SBFM) Makes NASDAQ Top Gainer List on News
April 2, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Sunshine Biopharma Inc. (NASDAQ:SBFM) a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals.

Biotech stock bioAffinity Technologies, Inc. (NASDAQ: BIAF) Makes NASDAQ Top Percentage Gainer on News
April 2, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the detection of early-stage lung cancer and other lung diseases

Biotech Stock Dermata Therapeutics, Inc. (Nasdaq: DRMA) Makes NASDAQ Top Gainer List on Positive Phase 3 Results
March 28, 2025 (Investorideas.com Newswire) Investorideas.com (www.investorideas.com), a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Dermata Therapeutics, Inc. (Nasdaq: DRMA, DRMAW), a late-stage biotechnology company focusing on the treatment of medical skin diseases and aesthetic applications.

Thursday's Trending Pharma Stock Plus Therapeutics, Inc. (Nasdaq: PSTV) Gains 170%
March 21, 2025 (Investorideas.com Newswire) Investorideas.com, a go-to platform for big investing ideas for stock traders, including biotech stocks reports on trading and news for Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system (CNS) cancers,ntral nervous system (CNS) cancers.

Subscribe to Biotech News RSS

Submit Articles   Search More Articles

Biotech Stock ETF's

First Trust NYSE Arca Biotech ETF ( NYSEArca: FBT ) The investment seeks investment results that correspond generally to the price and yield (before the fund's fees and expenses) of an equity index called the NYSE Arca Biotechnology Index(SM). The fund will normally invest at least 90% of its net assets plus the amount of any borrowings for investment purposes in common stocks that comprise the index. The index is an equal-dollar weighted index designed to measure the performance of a cross section of companies in the biotechnology industry that are primarily involved in the use of biological processes to develop products or provide services. The fund is non-diversified.

iShares US Healthcare ( NYSEArca: IYH ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Health Care Index (the "underlying index"), which measures the performance of the healthcare sector of the U.S. equity market. The fund is non-diversified.

iShares US Healthcare Providers ( NYSEArca: IHF ) The investment seeks to track the investment results of an index composed of U.S. equities in the healthcare providers sector. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. It seeks to track the investment results of the Dow Jones U.S. Select Health Care Providers Index (the "underlying index"), which measures the performance of the healthcare providers sector of the U.S. equity market. The fund is non-diversified.

iShares US Medical Devices ( NYSEArca: IHI ) The investment seeks to track the investment results of an index composed of U.S. equities in the medical devices sector. The fund seeks to track the investment results of the Dow Jones U.S. Select Medical Equipment Index (the "underlying index"), which measures the performance of the medical equipment sector of the U.S. equity market. The underlying index includes medical equipment companies such as manufacturers and distributors of medical devices such as magnetic resonance imaging (MRI) scanners, prosthetics, pacemakers, X-ray machines, and other non-disposable medical devices. The fund is non-diversified.

iShares Nasdaq Biotechnology ( NasdaqGIDS IBB ) The investment seeks to track the investment results of an index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. The fund generally invests at least 90% of its assets in securities of the underlying index and in depositary receipts representing securities of the underlying index. The underlying index contains securities of NASDAQ® listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals and that also meet other eligibility criteria determined by the NASDAQ OMX Group, Inc. The fund is non-diversified.

Market Vectors Biotech ETF ( NYSE MKT:BBH ) seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors® US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.

PowerShares Dynamic Biotech & Genome ETF ( NYSEArca: PBE ) The investment seeks investment results that generally correspond (before fees and expenses) to the price and yield of the Dynamic Biotechnology & Genome IntellidexSM Index. The fund generally will invest at least 90% of its total assets in common stocks of biotechnology companies and genome companies that comprise the underlying intellidex. The underlying intellidex was composed of common stocks of 30 U.S. biotechnology and genome companies. These companies are engaged principally in the research, development, manufacture and marketing and distribution of various biotechnological products, services and processes, etc. It is non-diversified.

Other Ideas - Guest Posts and / or sponsored financial content

Learn how to be published on our site: Buy a guest post on Investorideas.com

15 Features That Every Telehealth App Should Have for Both Patients and Doctors - February 19, 2025

Choosing the Right Dosage Form: Tablets, Capsules, or Liquids - January 30, 2025

Are Biohazard Remediation Services Worth Investing In? - November 29, 2024

Unleash Your Potential: Mojo Trek's Personalized Approach to Healthtech Recruitment - November 29, 2024

The Intersection of Business and Public Health: Why an MBA is Essential for Health Administrators - July 25, 2024

Nick Oberheiden and the Impella Heart Pump Cases - June 28, 2024

An Investor's Guide to Qualitative Analysis of Biotech Firms - June 18, 2024

How Healthcare Bookkeeping Services Elevate Your Business - March 27, 2024

The Rise of Mobile Applications in Healthcare and Medicine - September 5, 2023

How to Prove Wrongful Death - February 1, 2022

Healthcare Supply Chain Management Software - November 29, 2021

Overview of Biotech Stocks - What Could Happen by the End of 2021? - November 3, 2021

Consider Investing In These Disruptive Medical Companies In 2021 - April 16, 2021

Resources for Physicians and Medical Practices - December 31, 2020

Lockdown Part 2: The South African Economy and the Rand - December 15, 2020

How to Get Into Canada during COVID - November 30, 2020

The Impact of Gynecomastia on Your Mental Health and How to Deal With the Condition - September 8, 2020

Does Income Protection Cover Me for a COVID Redundancy? - August 10, 2020

Everything You Need to Know About Investing in Healthcare Stocks - March 30, 2020

The Rise Of The At-Home Testing Market - January 16, 2020

Why Do You Need Birth Injury Lawyer and How They Can Help You? - October 2, 2019

Biotech News from Newsfile

Optimi Health Announces $3.45 Million Convertible Financing and Extension of Secured Term Loan
Vancouver, British Columbia--(Newsfile Corp. - July 18, 2025) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Canadian drug manufacturer and formulator of GMP-grade MDMA and natural psilocybin, is pleased to announce that it has entered into subscription agreements pursuant to which it proposes to complete a non-brokered private placement (the "Offering") with two non-arm's length parties (each an "Investor") of 3,450 unsecured convertible debentures of...

Hemostemix Closing $3,000,000 Private Placement
Calgary, Alberta--(Newsfile Corp. - July 17, 2025) - Further to the June 26 and July 9th press releases announcing the Hemostemix Inc's (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") non-brokered private placement of $2,500,000 and its oversubscription, the Company has accepted additional over-subscriptions totalling $500,000. The Company is amending its filing with the TSXV for a private placement for gross proceeds of up to $3,000,000. Purchasers have subscribed for...

Maxwell Biosciences Announces AI Department & Hiring of Jon McClure
Austin, Texas--(Newsfile Corp. - July 17, 2025) - Maxwell Biosciences ("Maxwell"), a global health technology company pioneering immune-inspired small molecules called Claromers™, today announced new engineering leadership for its Artificial Intelligence efforts—further cementing its decade-long commitment to AI-first innovation. As part of this initiative, the company has appointed Jon McClure as Chief Technology Officer to accelerate the development of its AI-native platform for drug discovery...

NervGen Announces Leadership Transition to Support Strategic Growth and Expansion
Vancouver, British Columbia--(Newsfile Corp. - July 17, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF) (the "Company"), a clinical-stage biotechnology company developing innovative therapies for spinal cord injury (SCI) and other nervous system disorders, today announced a leadership transition as the Company enters the next phase of development for its first and potential best-in-class candidate, NVG-291.President and Chief Executive Officer Mike Kelly has stepped down as a director...

Izotropic Prepares New Platforms to Educate and Engage
- Strategic awareness initiatives underway ahead of IzoView commercialization -- Company podcast and breasct.com website in development to expand engagement -- Market-facing activities aligned with investor communications and corporate milestones -Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - July 15, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic" or the "Company"), a medical device company commercializing imaging-based products...

Subscribe to Biotech News